Viridian Therapeutics, Inc. VRDN Gross Assets/Liabilities

Gross Assets/Liabilities at other companies

AmgenAMGN

——

Roivant SciencesROIV

——

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Market cap$1.91B+82.0%

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilities.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Viridian Therapeutics, Inc.'s gross assets/liabilities?: Viridian Therapeutics, Inc. (VRDN) reported gross assets/liabilities of $12.5M in Q1 2026.